GENMAB A/S (GMAB) Form 6-K — Jun 29, 2026
Genmab A/S announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy. Results showed a 60% reduction in the risk of disease progression or death based on the primary analysis.
Key figures
- P value
- < 0.0001
- Hazard ratio
- 0.4
- Confidence interval
- [0.30, 0.55]
- Risk reduction percent
- 60
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.